XOMA, Dyax Cross-Licensing Antibody, Phage Display Rights
XOMA Ltd. entered its third antibody licensing deal of the year, this one an arrangement with Dyax Corp., which is providing not only payments but also access to its antibody library and a license to its important Ladner phage display patents. (BioWorld Today)
To continue reading subscribe now to BioWorld Today
Learn More about BioWorld Today
Already a subscriber? Sign In or Buy now to activate your subscription
Note: our contact information has changed
Customer Care: http://support.clarivate.com
© 2018 Clarivate Analytics.
Reproduction, reposting content is strictly prohibited.
Reproduction, reposting content is strictly prohibited.